Conatus Pharmaceuticals (CNAT) Crumbles: Stock Plunges by 18.7% - Tale of the Tape

Conatus Pharmaceuticals Inc. CNAT saw a big move last session, as the company's shares fell by nearly 19% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for CNAT as the stock is now up around 44% in the past one-month time frame.

Although this slump was obviously disappointing, the biotechnology company has seen 2 positive revisions and its current year loss consensus has narrowed down over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for CNAT. So make sure to keep an eye on this stock going forward to see if yesterday's price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.

CNAT currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the Medical Products industry include Cardica Inc. CRDC, ICU Medical, Inc. ICUI and NeuroMetrix Inc. NURO. All the three stocks carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

CONATUS PHARMA CNAT: Free Stock Analysis Report

CARDICA INC CRDC: Free Stock Analysis Report

ICU MEDICAL INC ICUI: Free Stock Analysis Report

NEUROMETRIX INC NURO: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Market News and Data brought to you by Benzinga APIs